*January 2025*
Data from a pooled analysis evaluating sunvozertinib (formerly DZD9008) show promising antitumor activity with a favorable safety profile for EGFR- tyrosine kinase inhibitor (TKI)-resistant non–small cell lung cancer (NSCLC). The pooled data come from 3 studies: the multinational phase 2 WU-KONG1 trial (NCT03974022), the phase 1 WU-KONG2 trial (CTR 20192097) and the phase 2 WU-KONG15 trial (NCT05559645).1
“Encouragingly, the pooled analysis has revealed the potential clinical value of sunvozertinib in EGFR TKI-resistant NSCLC,” said Xiaolin Zhang, PhD, CEO of Dizal. “Confronted with the challenge of resistance to third-generation EGFR TKIs, we will continue to advance our exploration in this area, aiming to bring new treatment options to patients with EGFR mutated NSCLC.”
The pooled analysis included a combined total of 40 patients with EGFR mutated NSCLC who had developed resistance to TKI treatment. Of these, 90% had received 3 or more prior lines of therapy with a median of 5 lines (range 1-16).1,2 All patients had received prior treatment with at least 1 type of EGFR TKI and 68.8% of patients received third generation EGFR TKI. Most patients also received prior chemotherapy (90.6%). Read more.
